RALEIGH, N.C., Feb. 26 /PRNewswire/ -- Arbor Pharmaceuticals, a specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company has launched XYLAREX - a first-in-class nonantibiotic for the dietary management of recurrent acute otitis media (middle ear infections). XYLAREX is a novel oral solution intended to be administered daily to reduce the number of ear infections children experience. The primary ingredient in XYLAREX has also been shown to reduce the amount of antibiotics prescribed to children affected by middle ear infections. XYLAREX can be administered to children as young as six months of age.
Acute Otitis Media (AOM) is the most common bacterial illness of childhood and the primary reason antibiotics are prescribed for children in the U.S. Recurrent AOM affects millions of U.S. children each year, and children suffering from repeated, painful ear infections are frequently exposed to numerous courses of antibiotics at a young age. With repeated antibiotic exposure there is an increased risk of developing bacterial resistance, which the Centers for Disease Control and Prevention (CDC) call one of the world's most pressing health concerns.
"Until now there have been limited options for managing children with recurrent acute otitis media. Pediatricians and otolaryngologists alike see many children with recurrent ear infections who have been subjected to countless antibiotic courses and - in severe cases - may require ear tube placement to alleviate symptoms. Parents and clinicians are looking for new options for these children. A novel, non-drug product like XYLAREX is an important new option for managing children with recurrent AOM in order to reduce their infections and decrease their need for antibiotics," says Mark Mehle, M.D., a practicing ear, nose, and throat physician in Cleveland, Ohio.
According to Jarrett Disbrow, President and CEO of Arbor Pharmaceuticals, "XYLAREX is a very important product as it represents a first-in-class non-drug therapy with the potential to positively impact the lives of millions of children suffering from recurrent ear infections. Arbor is firmly dedicated to health of children, and XYLAREX will be a significant addition for the management of common ear infections."
XYLAREX is available by prescription and can be obtained from retail pharmacies across the U.S. XYLAREX is being introduced to U.S. pediatricians by Arbor Pharmaceuticals' specialty sales force. XYLAREX is Arbor Pharmaceuticals' third product introduction since the company initiated commercial operations less than two years ago.
About Arbor Pharmaceuticals
Arbor Pharmaceuticals is a Raleigh, North Carolina-based specialty pharmaceutical company focused exclusively on the growing pediatric market. The company intends to become the leading pediatrics-focused pharmaceutical company by actively licensing, developing and commercializing late-stage products for significant pediatric conditions. The company currently focuses on nonantibiotic products for the treatment of various ear infections including ZINOTIC(R) for acute otitis externa and NEOTIC(R) for acute otitis media. XYLAREX is the latest addition to the Arbor Pharmaceuticals product portfolio and is indicated for the dietary management of recurrent acute otitis media.
To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.
CONTACT: Jarrett Disbrow, President and Chief Executive Officer of Arbor
Pharmaceuticals, Inc., +1-919-792-1701
Web site: http://www.arborpharma.com/
